{"id":7246,"date":"2016-01-11T05:22:56","date_gmt":"2016-01-11T05:22:56","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=7246"},"modified":"2016-01-11T05:22:56","modified_gmt":"2016-01-11T05:22:56","slug":"globaldata-says-vasculitis-treatment-market-value-will-rise","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/globaldata-says-vasculitis-treatment-market-value-will-rise\/","title":{"rendered":"Vasculitis Treatment Market Value will rise due to more effectual drug"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"color: #000000;\"><a href=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-7247\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg\" alt=\"download (1)\" width=\"284\" height=\"177\" title=\"\"><\/a>The treatment market for vasculitis, a rare inflammatory disease that changes the walls of blood vessels, is expected to see growth of a little more than five percent over the next 10 years,\u00a0<a style=\"color: #bf3b41;\" href=\"http:\/\/healthcare.globaldata.com\/media-center\/press-releases\/pharmaceuticals\/safer-more-effective-drugs-will-push-vasculitis-treatment-market-value-to-558-million-by-2024-says-globaldata\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">according to a new report from the research and consulting firm GlobalData.<\/span><\/a><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The author of the report, GlobalData\u2019s immunology analyst Alexandra Annis, explains this growth will happen due to the launch of five biologics with enhanced safety and efficacy profiles targeting different forms of the disease.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Current treatment strategies for vasculitis tend to involve the use of immunosuppressants like Methotrexate and Prednisone, which\u00a0<a style=\"color: #bf3b41;\" href=\"http:\/\/www.hopkinsvasculitis.org\/vasculitis-treatments\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">Johns Hopkins notes<\/span><\/a>\u00a0can be associated with a long list of harmful side effects, such as scarring of the liver or low red blood cell count.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cThe greatest unmet needs in the vasculitis market are improved safety and efficacy for both induction and maintenance therapies, as induction regimens for the management of vasculitis typically come with a considerable list of side effects, \u201cadds the analyst.<\/span><\/p>\n<p style=\"text-align: justify;\">[pullquote]Annis elaborates, saying that this new class of biologics will have four novel mechanisms of action (MOAs), which will benefit both patients and pharmaceutical companies.[\/pullquote]<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Annis elaborates, saying that this new class of biologics will have four novel mechanisms of action (MOAs), which will benefit both patients and pharmaceutical companies.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Patients won\u2019t have to deal with burdensome side effects while drug makers could reap big profits \u2014 although Annis says that the high cost of these biologics could hinder uptake in cost-conscious markets. \u00a0<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Annis highlights three companies and their respective drug candidates as having the best chance of success: Roche\u2019s Actemra, Bristol-Myers Squibb\u2019s Orencia, and GlaxoSmithKline\u2019s Nucala.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Roche gained a\u00a0<a style=\"color: #bf3b41;\" href=\"http:\/\/www.roche.com\/media\/store\/releases\/med-cor-2015-06-10.htm\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">breakthrough therapy designation<\/span><\/a>\u00a0for Actemra in June 2015 after demonstrating positive results in treating systemic sclerosis.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The FDA gave Nucala regulatory approval in November 2015 for treating a variant of\u00a0<a style=\"color: #bf3b41;\" href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/2015\/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">severe asthma<\/span><\/a>\u00a0whereas Orencia aims to\u00a0<a style=\"color: #bf3b41;\" href=\"http:\/\/www.orencia.bmscustomerconnect.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">help patients<\/span><\/a>\u00a0with rheumatoid arthritis.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The treatment market for vasculitis, a rare inflammatory disease that changes the walls of blood vessels, is expected to see growth of a little more than five percent over the next 10 years, according to a new report from the research and consulting firm GlobalData.<\/p>\n","protected":false},"author":6,"featured_media":7247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,17],"tags":[],"class_list":["post-7246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicine","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",95,59,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",284,177,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",96,60,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/01\/download-1.jpg",150,93,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"<a href=\"https:\/\/www.revoscience.com\/en\/category\/health\/medicine\/\" rel=\"category tag\">Medicine<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/research\/\" rel=\"category tag\">Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/7246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=7246"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/7246\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/7247"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=7246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=7246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=7246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}